flumazenil has been researched along with Multiple Sclerosis in 8 studies
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using positron emission tomography (PET) with [(11) C]flumazenil ([(11) C]FMZ), an antagonist of the central benzodiazepine site located within the GABAA receptor, we quantified and mapped neuronal damage in the gray matter (GM) of patients with multiple sclerosis (MS) at distinct disease stages." | 7.81 | The neuronal component of gray matter damage in multiple sclerosis: A [(11) C]flumazenil positron emission tomography study. ( Assouad, R; Bodini, B; Bottin, L; Bottlaender, M; Dollé, F; Freeman, L; Garcia-Lorenzo, D; Granger, B; Leroy, C; Louapre, C; Lubetzki, C; Papeix, C; Stankoff, B; Tourbah, A, 2015) |
| "Using positron emission tomography (PET) with [(11) C]flumazenil ([(11) C]FMZ), an antagonist of the central benzodiazepine site located within the GABAA receptor, we quantified and mapped neuronal damage in the gray matter (GM) of patients with multiple sclerosis (MS) at distinct disease stages." | 3.81 | The neuronal component of gray matter damage in multiple sclerosis: A [(11) C]flumazenil positron emission tomography study. ( Assouad, R; Bodini, B; Bottin, L; Bottlaender, M; Dollé, F; Freeman, L; Garcia-Lorenzo, D; Granger, B; Leroy, C; Louapre, C; Lubetzki, C; Papeix, C; Stankoff, B; Tourbah, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, Y | 1 |
| Rúa, SMH | 1 |
| Kaunzner, UW | 1 |
| Perumal, J | 1 |
| Nealon, N | 1 |
| Qu, W | 1 |
| Kothari, PJ | 1 |
| Vartanian, T | 1 |
| Kuceyeski, A | 1 |
| Gauthier, SA | 1 |
| Freeman, L | 1 |
| Garcia-Lorenzo, D | 1 |
| Bottin, L | 1 |
| Leroy, C | 1 |
| Louapre, C | 1 |
| Bodini, B | 1 |
| Papeix, C | 1 |
| Assouad, R | 1 |
| Granger, B | 1 |
| Tourbah, A | 1 |
| Dollé, F | 1 |
| Lubetzki, C | 1 |
| Bottlaender, M | 1 |
| Stankoff, B | 1 |
| Fernández, O | 1 |
| Fernández, V | 1 |
| Martinez-Cabrera, V | 1 |
| Mayorga, C | 1 |
| Alonso, A | 1 |
| León, A | 1 |
| Arnal, C | 1 |
| Hens, M | 1 |
| Luque, G | 1 |
| de Ramón, E | 1 |
| Caballero, A | 1 |
| Leyva, L | 1 |
| Gyódi, E | 4 |
| Benczur, M | 1 |
| Pálffy, G | 3 |
| Tálas, M | 1 |
| Petrányi, G | 3 |
| Földes, I | 1 |
| Hollán, SR | 1 |
| Milanov, I | 1 |
| Topalov, N | 1 |
| Kmetski, T | 1 |
| Kálmán, B | 2 |
| Takács, K | 2 |
| Kramer, J | 1 |
| Füst, G | 1 |
| Tauszik, T | 2 |
| Guseo, A | 2 |
| Kuntár, L | 2 |
| Komoly, S | 1 |
| Nagy, C | 2 |
8 other studies available for flumazenil and Multiple Sclerosis
| Article | Year |
|---|---|
A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis.
Topics: Adult; Case-Control Studies; Cohort Studies; Female; Flumazenil; Gray Matter; Humans; Immunity, Inna | 2020 |
The neuronal component of gray matter damage in multiple sclerosis: A [(11) C]flumazenil positron emission tomography study.
Topics: Adult; Carbon Radioisotopes; Female; Flumazenil; Gray Matter; Humans; Male; Middle Aged; Multiple Sc | 2015 |
Multiple sclerosis in Gypsies from southern Spain: prevalence, mitochondrial DNA haplogroups and HLA class II association.
Topics: Adolescent; Adult; Aged; Alleles; DNA, Mitochondrial; Female; Genes, MHC Class II; Genetic Predispos | 2008 |
Association between HLA B7, DR2 and dysfunction of natural- and antibody-mediated cytotoxicity without connection with the deficient interferon production in multiple sclerosis.
Topics: Adult; Antibody-Dependent Cell Cytotoxicity; Cytotoxicity, Immunologic; Female; Genes, MHC Class II; | 1982 |
Prevalence of multiple sclerosis in Gypsies and Bulgarians.
Topics: Adolescent; Adult; Aged; Bulgaria; Child; Child, Preschool; Epidemiologic Methods; Female; Humans; I | 1999 |
Sclerosis multiplex in gypsies.
Topics: Alleles; Complement C4a; Complement C4b; Female; HLA-B Antigens; HLA-B7 Antigen; HLA-DQ Antigens; HL | 1991 |
Association between the lack of HLA-DQw6 and the low incidence of multiple sclerosis in Hungarian Gypsies.
Topics: Ethnicity; HLA-DQ Antigens; Humans; Hungary; Multiple Sclerosis; Polymorphism, Restriction Fragment | 1990 |
Multiple sclerosis in 3 gipsy and 2 partly gipsy subjects (a clinical and immunogenetic study).
Topics: Adult; Ethnicity; Female; HLA Antigens; Humans; Hungary; Male; Middle Aged; Multiple Sclerosis; Roma | 1986 |